<DOC>
	<DOC>NCT02058472</DOC>
	<brief_summary>Study Design : randomized, open label, single-dose, 2-way cross-over design Phase : Phase I</brief_summary>
	<brief_title>Pharmacokinetic/Pharmacodynamic &amp; Safety Study of G3041 and SEVIKAR® Tablet in Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<criteria>healthy volunteers between the ages of 19 to 55 years old 19 ≤ BMI ≤ 27 having neither congenital/chronic diseases nor pathological symptoms/findings as results of medical examination doctor determines to be suitable as subjects within 4 weeks ago before administration Hypersensitivity(or history of hypersensitivity) to amlodipine and olmesartan Exceed 1.5 times of the upper limit of the reference range of AST, ALT, total bilirubin, γGT Excessive drinking(exceed alcohol 140g/week) Excessive caffeine(exceed 4cups/day) and grape fruit/orange juice(exceed 1cup/day) Smoking over 10 cigarettes per day</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>